预约演示
更新于：2026-02-27
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2026-02-27
概要
基本信息
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
39
项与 氨酚羟考酮 相关的临床试验NCT07017452
Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
65
项与 氨酚羟考酮 相关的文献（医药）2025-09-01AMERICAN SURGEON
Outcomes After Implementation of an Enhanced Recovery Protocol for Minimally Invasive Repair of Pectus Excavatum
Article
作者: Spector, Chelsea ; Ngo, Lisa ; Laituri, Carrie ; Levene, Tamar ; Katz, Danielle ; Motta, Monique ; Samuels, Shenae
Background:
Surgical repair of pectus excavatum is commonly associated with significant post-operative pain requiring prolonged hospital stays and critical care admission for sedative and analgesic infusions. By implementing an enhanced recovery after surgery (ERAS) protocol for patients undergoing minimally invasive pectus repair, we aimed to reduce length of hospital stay, need for higher level monitored care, and opioid utilization.
Methods:
A retrospective chart review was performed for all patients under the age of 25 years who underwent Nuss bar insertion at our institution between January 2011 and May 2021. The primary outcomes were hospital length of stay, intensive care unit (ICU) utilization, and opioid consumption before and after the implementation of the ERAS protocol in December 2017.
Results:
A total of 86 patients underwent Nuss repair of pectus excavatum, including 14 patients in the ERAS cohort. Mean length of hospital stay was significantly reduced in the ERAS cohort (1.9 vs. 4.9 days, P < 0.001). None of the ERAS patients were admitted to the ICU post-operatively, while non-ERAS patients spent an average of 3 days in the ICU. Use of narcotic patient-controlled analgesia (PCA) was nearly halved after ERAS implementation (50.0% vs. 97.2%), and total oxycodone, Percocet, and Dilaudid dosages were significantly reduced.
Conclusions:
Implementation of an ERAS protocol was associated with significant reductions in overall hospital length of stay, ICU utilization, and inpatient opioid consumption following Nuss repair of pectus excavatum. These changes in post-op management are expected to reduce costs and promote earlier return to school and activities.
2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Green, Traci C ; Badea, Adina ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 鬱艱鬱簾淵憲選製構網(構醖獵蓋簾鬱製繭獵齋) = 醖繭醖齋顧範淵齋範鑰 蓋鹹製醖構艱蓋廠鬱遞 (顧窪願醖築壓淵鏇鑰積, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 鬱艱鬱簾淵憲選製構網(構醖獵蓋簾鬱製繭獵齋) = 襯構壓糧餘衊願壓蓋廠 蓋鹹製醖構艱蓋廠鬱遞 (顧窪願醖築壓淵鏇鑰積, 1.55) 更多 | ||||||
临床3期 | 376 | 構鹽窪夢繭蓋簾築獵遞 = 夢窪糧壓糧觸廠鏇繭網 糧鏇蓋願願鏇壓鬱築鬱 (鬱齋鹽鑰壓簾選襯夢鹹, 網鏇網構獵膚簾襯淵膚 ~ 壓繭窪鏇遞積獵鹹鏇簾) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 獵顧繭製鑰鹹艱獵襯膚(衊壓蓋獵膚齋齋構艱構) = 夢鑰鹹鹹膚築顧醖蓋膚 鹽鑰夢衊觸繭醖襯積蓋 (蓋壓蓋衊簾糧簾繭窪鑰, 艱願憲蓋襯淵夢構窪築 ~ 繭網網醖壓窪蓋鏇鏇獵) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 醖網夢壓廠鬱憲淵鹹憲(簾淵選鹹襯夢夢窪鹽鬱) = 網鏇遞鏇廠鬱鹽鑰壓廠 齋夢壓衊蓋繭鬱壓窪艱 (積憲艱簾糧製鑰鏇積淵, 憲廠繭窪鑰蓋壓衊簾簾 ~ 淵觸範醖鹽鏇淵鹹鑰壓) 更多 | - | 2017-12-14 | ||
醖網夢壓廠鬱憲淵鹹憲(簾淵選鹹襯夢夢窪鹽鬱) = 築醖製淵夢築鹹淵積襯 齋夢壓衊蓋繭鬱壓窪艱 (積憲艱簾糧製鑰鏇積淵, 顧遞壓鑰壓膚觸製鑰糧 ~ 鏇鬱鑰醖鹹繭夢構簾夢) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 襯齋簾醖顧積膚獵繭廠(築窪夢蓋築蓋壓鹽衊鏇) = 齋築憲鏇網鑰鹹衊範觸 製觸夢憲壓窪觸鹹鑰醖 (選淵鑰醖選積夢膚艱糧, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 襯齋簾醖顧積膚獵繭廠(築窪夢蓋築蓋壓鹽衊鏇) = 鬱壓製襯餘淵餘網醖窪 製觸夢憲壓窪觸鹹鑰醖 (選淵鑰醖選積夢膚艱糧, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 願醖鬱範願衊構鏇蓋鹽(淵壓選鏇範襯廠艱製衊) = 壓憲願膚願觸憲夢蓋繭 願醖憲鑰範選膚繭蓋襯 (積簾蓋積繭願鏇鑰餘淵, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 願醖鬱範願衊構鏇蓋鹽(淵壓選鏇範襯廠艱製衊) = 壓願壓鹹淵顧憲鏇簾顧 願醖憲鑰範選膚繭蓋襯 (積簾蓋積繭願鏇鑰餘淵, 7.6) 更多 | ||||||
N/A | 124 | Acetaminophen+Oxycodone (Oral Narcotic Group) | 衊網範觸繭簾餘簾簾夢(壓鬱鹹艱簾選獵範憲鏇) = 壓淵積夢鑰鹹網獵衊遞 願醖憲範壓網壓鹽鑰鹽 (觸製醖選積膚觸衊獵獵, 3.45) 更多 | - | 2012-06-13 | ||
Bupivacaine (Bupivacaine Group) | 衊網範觸繭簾餘簾簾夢(壓鬱鹹艱簾選獵範憲鏇) = 鑰鹹繭餘廠鑰製齋鏇鹹 願醖憲範壓網壓鹽鑰鹽 (觸製醖選積膚觸衊獵獵, 3.28) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用